HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital bliss ... on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the non-denominational ... the ceremony was a reception, with music by the Moonlight Serenade Orchestra and a ...
(Date:8/4/2015)... ... August 04, 2015 , ... Dr. Gary Richter, ... America’s Favorite Veterinarian. The contest is put on by the American Veterinary Medical ... nominees. Nominees were evaluated on community involvement, ethical behavior, passion for profession, and ...
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices ... medical device lawsuit claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As ... federal cases for Cook IVC Filter clients under In re Cook Medical, Inc., IVC ...
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing Education Company ... of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing ... Learning Institute Inc. and EDUmotion US LLC. , This special activity was recently ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3
(Date:8/3/2015)... 4, 2015   The Intellectual Property and ... leading provider of intelligent information for businesses and ... CMR Pharmaceutical R&D Factbook , the biopharmaceutical industry,s ... around declines in R&D, the analysis identifies a ... milestone and forecasts sales to reach $1.3 trillion ...
(Date:8/3/2015)... , Aug. 3, 2015 Discovery Laboratories, ... company focused on developing aerosolized KL4 surfactant therapies ... and webcast at 8:30 a.m. Eastern Time on Tuesday ... discuss the 2015 second quarter financial results along ... issue a press release announcing the second quarter ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
Cached News: